Pharmaceutical market
I s P h a r m a a s i m p o r t a n t a s i t s e m p l o y e e s t h i n k?
Our lives are getting longer In Europe, over the last 65 years, we have obeserved a significant increase in life expectancy Life expectancy in Europe (1950-2015)
Demographic changes in the EU an ever- greater challenge for healthcare Demographic development in EU-28 countries The predicted increase of cancer incidence in the world
It is a big economic and social problem Chronic diseases constitute the main health cost item and, if uncontrolled, they are a growing risk factor The share of chronic disease treatment costs in total healthcare expenditure Risk factor growth (obesity, urbanisation, aging) The share of chronic disease costs in total healthcare expenditure ~75% of European health expenditure goes to the treatment of chronic diseases and amounts to 700 billion. Chronic diseases such as cardiac disorders, diabetes, lung diseases and Alzheimer s disease are a big financial burden on the healthcare system due to increased annual expenditure.
It is a big economic and social problem and it is going to get rather worse Lost income due to absenteeism; European countries with high income levels are affected most Estimated chronic disease costs, 2011-2030 Disability and healthy life years, Europe
This challenge is being addressed with innovative therapies The contribution of innovative medicine to life expectancy increase (2004-2009) In the years 2000-2009 an increase in life expectancy by 1.74 years was observed in the population of 30 OECD (Organisation for Economic Cooperation and Development) countries. Innovative medicine is estimated to have contributed to 73% of this growth in life expectancy among other analysed factors (e.g. income, education, vaccines, risk factor reduction, access to the healthcare system).
Let s not forget about diagnostics Data gathered in the USA shows that improvement in the treatment and early detection of neoplasms contributes to an increase in the survival rate of cancer patients 5-year survival rate, one year after diagnosis (%)
Pharmaceutical companies invest The pharmaceutical industry invests considerable sums in its search for solutions to key medical problems... Share of EMA Marketing Approvals 1995-2000 Share of EMA Marketing Approvals 2007-2012
in innovative new medical devices Development of innovative medical devices that respond to patient preferences, Improved patient-doctor cooperation and reduced treatment costs Patients with type II diabetes show a strong preference for oral administration vs injections The development of insulin pumps has decreased healthcare costs and improved patient-doctor cooperation
WHAT IS DIABETES? Diabetes is a chronic disease in which the pancreas does not produce enough insulin or the insulin produced is not properly utilized by the human body cells. People need energy for their daily mental and physical activities. In order for individual cells to consume glucose as energy source, insulin must be present in blood. SYMPTOMS - fatigue, - weakness, - polyuria, - increased thirst, - excessive appetite - weight loss, - in the elderly, the disease may be mild, latent, without characteristic symptoms - it does not hurt. CLASSIFICATION OF DIABETES Type 1 diabetes - is characterized by an absolute lack of insulin, occurs in younger people, most often in children and adolescents, usually begins suddenly, and the only method of treatment is the administration of insulin. Type 2 diabetes - the most common form of this disease, affects 90% of all diabetic patients, usually develops in people over the age of 40, who are obese, have a family history of diabetes. Initially, the disease is asymptomatic. Dietary restriction, exercise, oral antidiabetic drugs are used. It is usually necessary to use insulin after several years. LECZENIE lifestyle change, implementation of the principles of healthy eating, therapeutic physical exercise, self-control, systematic medical supervision, pharmacotherapy (oral medications or insulin). COMPLICATIONS OF DIABETES Long-term high sugar levels cause damage to small blood vessels and large arteries. This leads to a disorder of blood supply and damage to many organs. The consequences of this process are the chronic complications of diabetes: - diabetic retinopathy is the damage to the visual system associated with lesions in the retina, resulting in visual impairment. - diabetic nephropathy - involves damage to the kidneys, specifically the glomeruli responsible for blood filtration and the removal of unnecessary metabolic products from the body. This process, which lasts for a dozen or several dozen years gradually leads to renal failure. - diabetic neuropathy - is the damage to nerves over the course of the illness. Most often it is peripheral polyneuropathy, which manifests itself in a burning sensation in the feet and hands, mostly at night. Diabetes accelerates the formation of atherosclerotic lesions in blood vessels, leading to the development of coronary heart disease, ischemic disease of the lower limbs and stroke.
in new innovative medical devices Development of innovative medical devices that respond to patient preferences, Improved patient-doctor cooperation and reduced treatment costs Patients with type II diabetes show a strong preference for oral administration vs injections The development of insulin pumps has decreased healthcare costs and improved patient-doctor cooperation
in innovative technologies Social media has improved the standard of contact with patients and provided new possibilities for the support of both patients and doctors Development of mobile medical devices In Europe, patients with diabetes were not receiving proper glycemic contol, which was associated with a growing risk of severe vascular complications. The therapeutic results in these patients are strictly dependent on blood glucose control, however, most of them did not comply with therapeutic indications. The industry s response The pharmaceutical industry responded to the need for a more comfortable method of blood glucose control and came up with mobile devices facilitating the continuous and easy measurement of blood glucose levels. Regular self-monitoring of blood glucose (SMBG) by patients allows for the achievement of the goals of the therapy. ibgstar is an integrated system of blood glucose level monitoring providing measurement, the storage and transmission of data as well as data management through iphone applications. The normal glycated haemoglobin value is below 6.5-7
The pharmaceutical industry invests mainly in innovation (R&D) The ranking of expenditure on R&D (% of net sales, 2013)
The pharmaceutical industry is a leader among employers The pharmaceutical industry bases its activity on research/innovation and uses highly advanced manufacturing technologies, thus, it is an attractive employer in Europe Employment in the pharmaceutical industry, EU (1990-2014)
And where is ROCHE in all that?
1. A ranking of the world s 25 largest pharmaceutical and biotechnological companies. The ranking authors considered: income profit assets
2.
3.
4.
5. 6. 7.
10. 8. 9.
13. 11. 12.
14. 16. 15.
17. 19. 18.
22. 20. 21.
25. 23. 24.
Roche Medicinal products Portfolio: 30 preparations, for such fields as: Oncology Nephrology Transplantology Rheumatology Neurology Cardiology Infectious diseases Diabetology Diagnostics
Personalised medicine: Herceptine trastuzumab (breast cancer and stomach cancer) Zelboraf vemurafenib (skin melanoma) Tarceva erlotinib (lung cancer) Roferon A recombined interferon alfa (renal cancer, leukaemia, lymphoma, melanoma) Xeloda capecitabine (intestinal cancer, stomach cancer, breast cancer) Avastin bevacizumab (colon cancer, breast cancer, lung cancer, ovarian cancer, renal cancer) Erivedge vismodegib (skin cancer) Perjeta pertuzumab (breast cancer)
Virusology Roferon A (hepatitis B and C, HIV) Invirase (HIV) Viracept (HIV) Pegasys (hepatitis B and C) Tamiflu (flu prophylactics and treatment) Fuzeon (HIV) Copegus (hepatitis C)
The pharmaceutical market Researching and introducing new medicines influences: Life expectancy in the population Improvement in the quality of the gained years Scientific development and progress in healthcare Diagnostics and therapy of chronic diseases and so called new diseases Personal, social and economic cost reduction Investment in the R&D sector facilitates: Technological development (medical devices, diagnostic equipment and new technologies) Better access to current therapies Improvements in current treatment effectiveness The introduction of new routes of administration (e.g. inhalation therapy: asthma, COPD; diabetology etc.) enhancing their efficiency Education of (health professionals, patients, consumers) allows for: Enhancing social awareness (of health: diseases, prevention, healthy habits) Disease prevention (e.g. through vaccines) Prophylactics Reduction of incidence, alleviation of symptoms